Key result
SGLT2 inhibitors demonstrated positive clinical impact in patients with heart failure with reduced ejection fraction, irrespective of type 2 diabetes status.
Why the study?
Heart failure prevalence is rising globally, and recent trials have shown positive clinical impacts of SGLT2 inhibition in heart failure with reduced ejection fraction with and without type 2 diabetes.
Do SGLT2 inhibitors improve clinical outcomes in patients with heart failure with reduced ejection fraction, irrespective of type 2 diabetes status?
Do SGLT2 inhibitors improve clinical outcomes in patients with heart failure with reduced ejection fraction, irrespective of type 2 diabetes status?
This review highlights the positive clinical impact of SGLT2 inhibitors in HFrEF patients regardless of diabetes status, supporting their use in clinical practice.
May support SGLT2 inhibitor use in nondiabetic HFrEF; leaves open optimal timing and long-term outcomes.
Heart failure is a shared chronic phase of many cardiac diseases and its prevalence is on the rise globally. Previous large-scale cardiovascular outcomes trials of sodium.glucose co-transporter 2 (SGLT2) inhibitors in patients with type 2 diabetes (T2D) have suggested that these agents may help to prevent primary and secondary hospitalisation due to heart failure and cardiovascular death in these patients. Data from the Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure (DAPA-HF) and Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Reduced Ejection Fraction (EMPEROR-Reduced) have demonstrated the positive clinical impact of SGLT2 inhibition in patients with heart failure with reduced ejection fraction both with and without T2D. These data have led to the approval of dapagliflozin for the treatment of patients with heart failure with reduced ejection fraction, irrespective of T2D status. This article reviews the latest data reported from the DAPA-HF and EMPEROR-Reduced trials and their clinical implications for the treatment of patients with heart failure.
No takes yet. Share an insight, caveat, or question.
Rosano et al. (2020) conducted a review in Heart failure with reduced ejection fraction. Sodium-glucose co-transporter 2 (SGLT2) inhibitors was evaluated. SGLT2 inhibitors demonstrated positive clinical impact in patients with heart failure with reduced ejection fraction, irrespective of type 2 diabetes status.